文献速递湿疹皮炎与荨麻疹

特应性皮炎系统治疗随机对照试验中外用合并及补救治疗的报告:范围综述

Reporting of concomitant and rescue topical therapies in randomized controlled trials evaluating a systemic treatment in atopic dermatitis: a scoping review.
PubMed 文献 · Br J Dermatol · 2025-01-01

该范围综述纳入1991至2023年发表的67项特应性皮炎系统治疗随机对照试验,评估外用合并及补救治疗的报告情况。多数试验充分报告了合并外用的允许或禁止(96%),但补救外用的报告较低(73%),且 potency、疗程、频率、用量及启用标准等细节报告不足。仅发表年份≥2020与补救外用报告较好相关。

要点

  • 多数试验报告了合并外用允许/禁止(96%),补救外用报告较低(73%)。
  • 合并外用中 potency、疗程、频率、用量报告率分别为89%、54%、34%、6%。
  • 补救外用中仅24%明确启用标准,62%使用「研究者酌情」表述。

核心结论

  • 多数特应性皮炎系统治疗随机对照试验报告了合并外用治疗,但补救外用的报告不一致且不充分。
  • 需要标准化报告方法以提高特应性皮炎试验的透明度和可解释性。

研究设计与样本

  • 范围综述,纳入近期一项动态系统综述中的特应性皮炎系统免疫调节治疗随机对照试验。
  • 共筛选83项试验,纳入67项发表于1991至2023年的随机对照试验。
  • 仅纳入抗炎外用治疗,未考虑润肤剂。

主要发现

  • 合并外用允许或禁止的充分报告为64/67(96%),补救外用为49/67(73%)。
  • 允许合并外用的试验均报告类型,但 potency 31/35(89%)、疗程19/35(54%)、频率12/35(34%)、用量2/35(6%)。
  • 允许补救外用的试验中类型31/34(91%)、potency 18/34(53%)、疗程3/34(9%)、频率2/34(6%)、用量0/34(0%)。
  • 仅8/34(24%)明确报告补救外用启用标准,21/34(62%)使用「研究者酌情」。
  • 多变量 logistic 回归中仅发表年份≥2020与补救外用报告较好相关(调整 OR 9.55,95%CI 1.76-39.80)。

关键数值与推荐

  • 合并外用允许或禁止报告:64/67(96%)。
  • 补救外用允许或禁止报告:49/67(73%)。
  • 补救外用启用标准明确报告:8/34(24%)。
  • 发表年份≥2020与补救外用报告较好相关:调整 OR 9.55(95%CI 1.76-39.80)。

临床怎么用

  • 解读特应性皮炎系统治疗试验时需关注补救外用使用的不平衡可能影响结果解释。
  • 报告系统治疗试验时应详细描述合并及补救外用的类型、potency、疗程、频率、用量和启用标准。

局限性

  • 仅纳入抗炎外用治疗,未考虑润肤剂。
  • 纳入试验来自近期一项动态系统综述,可能未涵盖所有相关随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized controlled trials (RCTs) evaluating new systemic treatments for atopic dermatitis (AD) have increased dramatically over the last decade. These trials often incorporate topical therapies either as permitted concomitant or rescue treatments. Differential use of these topicals postrandomization introduces potential bias as they may nullify or exaggerate treatment responses. OBJECTIVES: To determine the proportion of RCTs that clearly report the allowance or prohibition of concomitant and rescue topical treatments; and to examine the reporting of specific key parameters for these topicals. METHODS: We included RCTs of systemic AD medication included in a recent living systematic review. Inclusion criteria were published RCTs evaluating systemic immunomodulatory treatments in AD. Only anti-inflammatory topical therapies were included treatments in this review; emollients were not considered. RESULTS: We screened 83 AD trials and included 67 RCTs published between 1991 and 2023. The majority adequately reported the allowance or prohibition of concomitant topical treatments (n = 64/67; 96%), but this clarity was less prevalent with regard to rescue topicals (n = 49/67; 73%). All trials that permitted concomitant treatments consistently reported the type, although details on potency (n = 31/35; 89%), duration (n = 19/35; 54%), application frequency (n = 12/35; 34%) and quantity (n = 2/35; 6%) were less frequently reported. Similarly, trials that allowed rescue treatments often specified the type (n = 31/34; 91%) but provided limited information on potency (n = 18/34; 53%), duration (n = 3/34; 9%), application frequency (n = 2/34; 6%) and quantity (n = 0/34; 0%). Notably, only 24% (n = 8/34) clearly reported the criteria for using rescue topical treatments, with the phrase 'at investigator's discretion' used in most cases (n = 21/34; 62%). In the multivariable logistic regression analysis including impact factor, the journal's policy on adhering to CONSORT guidelines, publication year, funding, number of patients randomized and blinding status, only publication year (≥ 2020) was associated with having better reporting for rescue topical treatments (adjusted odds ratio 9.55, 95% confidence interval 1.76-39.80). CONCLUSIONS: While most clinical trials of systemic treatments in AD report concomitant topical treatments, reporting practices for rescue topicals are less consistent and inadequate. A standardized approach to reporting topical treatment in AD trials is needed to enhance transparency and interpretability. Eczema is one of the most common skin diseases worldwide. Sometimes medicines called ‘systemic medication’ (tablets or injections that affect the whole body) are needed to control eczema. A type of study called ‘clinical trials’ is carried out to test the benefits and harms of such treatments in people with eczema. In these studies, participants are often allowed to use the cream they would usually apply to control their eczema. Such creams include medicines called steroids or calcineurin inhibitors. These creams can be used at the same time as the systemic medicine or only when the eczema flares (called ‘rescue treatment’). Reporting what was done is important if one group ends up using more creams than another. We are researchers in the UK and France. We wanted to know how well the use of flare control creams is reported in clinical trials of people with eczema. We looked at the 67 clinical trials that investigated systemic medicines for eczema published up to March 2023. We found that although most studies reported whether flare control creams were allowed alongside the medicine being studied, most did not clearly say whether these creams were used as a rescue treatment. We also found that other important things like how often, how much, how strong or how long the flare control creams were used were not so well reported. Our findings suggest that better reporting of use of flare creams in clinical trials is needed.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Leducq S, Fong WCG, Williams HC, et al. Reporting of concomitant and rescue topical therapies in randomized controlled trials evaluating a systemic treatment in atopic dermatitis: a scoping review. Br J Dermatol. 2025. PMID: 39883519. doi:10.1093/bjd/ljaf031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。